The TIDES Manufacturing Mandate: Why Incrementalism Fails and Integration Prevails

As TIDES (Peptides and Oligonucleotides) therapeutics enter the chronic disease era, conventional batch manufacturing cannot fully meet demands for scale, purity, and speed. Asymchem recognized that piecemeal improvements to existing manufacturing models offers limited support to next generation TIDES manufacturing; instead, we have adopted a fully integrated approach—covering upstream innovation, downstream optimization, and oral delivery. Asymchem's end-to-end TIDES manufacturing ecosystem reduces costs, accelerates timelines, and de-risks commercial production for next-generation peptides and oligonucleotides.

Key Highlights
• Upstream – Tag-assisted & AI-driven chemoenzymatic synthesis
• Downstream – Continuous processing to eliminate bottlenecks
• Oral Delivery – Patient-friendly formulation technologies
• Integration – Unified R&D and manufacturing network from start to scale

Download the full white paper to see how integrated TIDES manufacturing can accelerate your program.